This product is indicated for the treatment of acute or chronic schizophrenia dominated by positive symptoms (delirium, hallucination, cognitive impairment, etc.) and/or negative symptoms (psychomotor retardation, apathy, social withdrawal, etc.). It is also effective for schizophrenia characterized by negative symptoms.
This product is indicated for the treatment of schizophrenia. Olanzapine can maintain its basic clinical efficacy during maintenance treatment in patients responsive to the initial treatment. It is also indicated for the treatment of moderate to severe manic episodes and the prevention of relapse in bipolar affective disorder.